Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Here's What's Lifting Seres Therapeutics Inc.'s Stock Price Today

What happened

Shares of Seres Therapeutics Inc. (NASDAQ: MCRB  )  a clinical-stage biotech developing unique therapies that address dysfunctional microbiomes, are responding well to the announcement of a do-over granted by the Food and Drug Administration. The stock was up 35.2% as of 11:52 a.m. EDT during Thursday's session.

So what 

It's a well-known fact that physicians should do more with bacteria and other microbes than destroy them with antibiotics. Unfortunately, stepping into uncharted regulatory territory is an uphill climb in an already challenging industry. This is why investors were thrilled to hear that the FDA will allow another trial with its lead candidate, SER-109, for the treatment of patients with recurrent Clostridium difficile infections.

Money falling from sky on a happy person

Image source: Getty Images.

Last summer, SER-109 failed to significantly reduce the rate of infection recurrence benefit versus placebo. The candidate is an ecosystem of bacterial spores intended to help revive patients' microbial flora to a more natural state following treatment with antibiotics. While this approach makes perfect sense in theory, a failure to prove its efficacy in practice decimated the stock.

Now what

After meeting with the FDA to discuss a path forward, the company intends to begin a new and improved phase 2 study with a lot more patients and a much higher dose of the experimental therapy. It also contends that the trial might be sufficient to support a new drug application if the trial is a success.

The rapid rise of antibiotic-resistant infections is one of the largest threats to public safety, and the medical community is clamoring for better solutions. If Seres can score with SER-109, the stock could produce huge gains in the long run. 

Seres also reported full-year financial results, which included a $91.6 million loss last year. At this rate, the $230 million in cash, cash equivalents, and investments on its books at the end of 2016 should be enough to keep the lights on through 2018. With a bit of luck, we'll know whether it has a winner on its hands before it needs to dilute shares to raise more capital.

10 stocks we like better than Seres Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Seres Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008449, ~/Articles/ArticleHandler.aspx, 3/25/2017 1:49:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20596.7 -59.9 -0.3%
Change down S&P 500 2344.0 -2.0 -0.1%
Change up NASD 5828.7 11.0 0.2%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/24/2017 4:00 PM
MCRB $10.83 Up +0.12 +1.12%
Seres Therapeutics CAPS Rating: **